The results, published in Nature, strengthen oncologists' understanding of Enhertu's clinical activity as a second-line ...

The combination did not benefit a biomarker unselected population, but those with mismatch repair-deficient tumors had extended disease-free survival.

A study presented at the ESMO Congress shed light on an ADC directed against an immune checkpoint in PD-L1-expressing solid ...

The Phase II results bolster the firm's confidence in the c-MET expression cutoff it has established in an ongoing Phase III trial of the drug.

The organizations will work together to develop technologies and processes related to early cancer screening, preventive care, and precision medicine.

The company said it will lay off approximately 37 percent of its workforce and stop all clinical development as it explores strategic alternatives.

Three months after treatment with troculeucel, two patients in the Phase I portion went from having moderate to mild symptoms of dementia.

Sanofi will gain exclusive rights to commercialize the lead-212-based radiopharmaceutical AlphaMedix in somatostatin-expressing neuroendocrine cancers.

NEW YORK – A survey of professionals developing cancer drugs found that while precision oncology is a major area of focus at pharmaceutical companies, there are varying views as to the extent these ...

NEW YORK – A multicenter research effort is underway to develop a platform and monitoring system for preventing adverse drug interactions due to patients' genetic, environmental, and lifestyle factors ...